Identification of novel bacteriocin against Staphylococcus and Bacillus species
Abstract
Objectives: Due to the continues emergence of antimicrobial resistance, discovery of novel compounds are urgently required. Thus, this study is focused to identify a novel antimicrobial peptide (bacteriocin) targeting multidrug-resistant pathogenic bacteria.
Methods: About 80 environmental isolates were recovered and screened for anti-bacterial activity using simultaneous antagonism assays. Produced peptide (AB3) was purified using Strata-XL-C and Sep-Pack columns. Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) analysis and MIC were conducted on the AB3 peptide to determine its molecular weight and spectrum of activity. Extraction and amplification for the 16S rRNA gene of the producing strain was accomplished using QIAamp DNA Mini Kit and GeneAmp PCR system thermocycler, respectively. Novelty of the compound was assessed based on all obtained genomic and proteomic data using Basic Local Alignment Search Tool search and Unni-Prot and Bactibase, respectively.
Results: About 5% of screened isolates showed antagonistic activity toward tested indicators. Obtained compound showed narrow spectrum of activity toward certain Gram-positive species including, methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA) and Bacillus species. MALDI-TOF
analysis revealed the flowing molecular masses: 1288.207 Da, 1304.536 Da, 1326.529 Da, 1403.591 Da, and 1472.792 Da. The extensive genomic and proteomic analysis have indicated the discovery of novel bacteriocin produced by Bacillus malacitensis.
Conclusion: A novel bacteriocin (AB3) was identified from B. malacitensis, which has showed promising in vitro bactericidal activity toward MSSA, MRSA, and Bacillus subtilis. This compound holds great potential to replace or used in combination with currently used antibiotics to treat serious untreatable bacterial infections. However, further investigations to determine its suitability for therapeutic use in human health are needed.
Keywords:
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).